Article Text
PDF
Statistics from Altmetric.com
- CCNE, National Consultative Ethics Committee for Health and Life Sciences
- HFEA, Human Fertilisation and Embryology Authority
- HLA, human leucocyte antigen
- ITA, Infertility Treatment Authority
- IVF, in vitro fertilisation
- PGD, preimplantation genetic diagnosis
- preimplantation genetic diagnosis (PGD)
- tissue typing
- genetic test
- genetic status
- right not to know
- interests
When is commodification acceptable?
Preimplantation genetic diagnosis (PGD) is usually restricted to couples who are eligible for in vitro fertilisation (IVF)—infertile couples or those with a history of genetic disease. The Human Fertilisation and Embryology Authority (HFEA) in England and the Infertility Treatment Authority (ITA) in Australia have both given permission for PGD with tissue typing to detect human leucocyte antigen (HLA) compatibility in order to save an existing sibling with a life threatening condition. The procedure has also been carried out in the United States.1
Heavy criticism followed the February 2002 ruling of England’s HFEA to allow a family to try for a child who is free of thalassaemia and a “perfect match” for a sick sibling.2 Then in August …
Read the full text or download the PDF:
Other content recommended for you
- Britain’s new preimplantation tissue typing policy: an ethical defence
- Preimplantation HLA typing: having children to save our loved ones
- “Saviour siblings”
- Ethics of using preimplantation genetic diagnosis to select a stem cell donor for an existing person
- Is conceiving a child to benefit another against the interests of the new child?
- Extending preimplantation genetic diagnosis: medical and non-medical uses
- Preimplantation genetic testing
- The right not to know and preimplantation genetic diagnosis for Huntington’s disease
- Ethics briefings
- A brief and personal history of ‘what’s in a name’ in reproductive genetics